• /
Population   L M H
Intervention L M H
Comparison L M H
Outcome       L M H
Keywords        P I O Ex
Subbarao_2021_33769252

Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021.
Authors: Sathyavani Subbarao, Lenesha A Warrener, Katja Hoschler, Keith R Perry, Justin Shute, Heather Whitaker, Michelle O'Brien, Frances Baawuah, Paul Moss, Helen Parry, Shamez N Ladhani, Mary E Ramsay, Kevin E Brown, Gayatri Amirthalingam
Published on: Mar 2021   Publication: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin; 26(12)
DOI: 10.2807/1560-7917.ES.2021.26.12.2100329

Sera were collected from 185 adults aged ≥ 70 years in London to evaluate the immune response to COVID-19 vaccines . A single dose of Pfizer/BioNtech vaccine resulted in> 94% seropositivity after 3 weeks in naïve individuals using the Roche Spike antibody assay, while two doses produced very high spike antibody levels, significantly higher than convalescent sera from mild-to-moderate PCR-confirmed adult cases . Our findings support the United Kingdom's approach of prioritising the first dose and delaying the second dose of COVID-19 vaccine.

Index: Antibody, COVID-19, COVID-Vaccine, Immunity, Pfizer/BioNtech, Spike Protein

Article Analysis:
--
No tags are applied.
Journal:
Journal Article
Source:
PubMed: 33769252
issn_isbn:
1560-7917
Country:
Sweden
Language:
eng
article_id: 660420